Finch Therapeutics pauses Phase 3 PRISM4 trial; FDA clinical hold on CP101; dosing occurred while hold in effect

Finch Therapeutics Group, Inc.

FDA clinical hold letter Feb 24, 2022 requesting additional info on SARS-CoV-2 donor screening protocols.
Company paused enrollment in PRISM4 Phase 3 trial of CP101 for recurrent C. difficile infection.
Company informed FDA that participants were dosed while clinical hold was in effect; conducting a review of the matter.
FDA letter did not reference any adverse clinical outcomes in Finch's trials.
Company evaluating impact on timing of expected topline data readout from PRISM4.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.